Compare McKesson Corporation (MCK) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? McKesson Corporation trades at $930 (market cap $108.46B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.03 (market cap $323.80B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 3× McKesson Corporation's market cap, and McKesson Corporation pays a 0.4% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Vanguard Tax Managed Fund FTSE Developed Markets ETF for 131 Days on average.
| MCK | VEA | |
|---|---|---|
Market Cap | $108.46B | $323.80B |
Volume | 712,607 | 17,001,112 |
Sector | Health | — |
52-Week High | $995.69 | $73.79 |
52-Week Low | $725.17 | $58.90 |
Typical Hold Time | 74 Days | 131 Days |
Enterprise Value | $115.00B | — |
Dividend Yield | 0.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Vanguard FTSE Developed Markets ETF (VEA) trades at $70.26, down 1.2% today, with a bearish technical signal from moving averages. The ETF offers exposure to developed markets outside the U.S. with a low 0.03% expense ratio and a recent dividend declared for September 2026. Recent news highlights its cost advantage over peers and mixed institutional activity, with some firms increasing stakes while others reduced positions.
VEA provides diversified international exposure at minimal cost, but near-term technical weakness and reliance on global economic stability pose risks. The fund's appeal lies in its efficiency and yield, yet investors face currency and geopolitical uncertainties inherent in non-U.S. markets. Long-term prospects depend on sustained growth in developed economies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
